Prana Biotechnology is developing first-in-class therapies to treat orphan neurodegenerative diseases.
Prana’s lead candidate, PBT434, is the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. PBT434 has been shown to reduce abnormal accumulation of α-synuclein and tau proteins in animal models of disease by restoring normal iron balance in the brain. In this way, it has excellent potential to treat various forms of atypical parkinsonism such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP).
PBT434 will enter the clinic with a Phase 1 study in healthy volunteers in mid-2018 and thereafter in a study of patients with MSA and PSP. There is no known cure for either disease and no current treatments for slowing disease progression.
Prana Biotechnology was incorporated in Melbourne, Australia in 1997 and has offices in Melbourne, Australia, and San Francisco. The Company listed on the Australian Securities Exchange (ASX: PBT) in 2000 and listed on the NASDAQ (NASDAQ: PRAN) in 2002.
Board of Directors
Prana has a well established Board of Directors with extensive experience in the research, pharmaceutical and financial industries.
Research and Development Advisory Board
The Research and Development Advisory Board is composed of scientists with professional expertise in research. These scientific advisors provide advice regarding the Company‘s proposed research and development activities
Chief Scientific Advisor, Scientific Co-Founder, Professor of Neurology, Harvard Medical School
Chair of the Psychiatry of Ageing and Director of the Centre for Dementia Prevention at the University of Edinburgh
Mental Health Research Institute; Laureate Professor at the University of Melbourne